Marker Therapeutics (MRKR) Invested Capital (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Invested Capital data on file, last reported at $13.8 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $13.8 million, down 4.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.8 million (down 4.8% YoY), and the FY2025 annual result was $16.8 million, down 9.49% from the prior year.
• Invested Capital declined to $13.8 million in Q1 2026 per MRKR's latest filing, from $16.8 million in the prior quarter.
• Over five years, Invested Capital peaked at $36.0 million in Q2 2022 and troughed at $7.4 million in Q3 2024.
• A 5-year average of $18.2 million and a median of $16.7 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2025: Invested Capital slumped 55.43% in 2023, then soared 146.84% in 2025.
• A 5-year view of Invested Capital shows it stood at $22.1 million in 2022, then plunged by 36.42% to $14.1 million in 2023, then surged by 32.06% to $18.6 million in 2024, then declined by 9.49% to $16.8 million in 2025, then decreased by 17.87% to $13.8 million in 2026.
• Business Quant data shows MRKR's Invested Capital at $13.8 million in Q1 2026, $16.8 million in Q4 2025, and $18.4 million in Q3 2025.